Key result
First-trimester second-generation antipsychotics are not linked to increased major congenital malformations versus no exposure.
Why the study?
The risk of major congenital malformations after first-trimester gestational exposure to second-generation antipsychotic drugs was uncertain based on prior studies and meta-analyses.
Does first-trimester gestational exposure to second-generation antipsychotic drugs increase the risk of major congenital malformations in pregnant women?
Does first-trimester gestational exposure to second-generation antipsychotic drugs increase the risk of major congenital malformations in pregnant women?
First-trimester exposure to second-generation antipsychotics does not appear to significantly increase the risk of major congenital malformations, supporting their use when clinically indicated.
No takes yet. Share an insight, caveat, or question.
Reassures on major malformation risk with first-trimester second-generation antipsychotics; leaves open need for larger confirmatory studies.
Chittaranjan Andrade (2021) conducted a review in Pregnancy. Second-generation antipsychotic (SGA) drugs vs. No exposure or first-generation antipsychotics was evaluated on Major congenital malformations. First-trimester exposure to second-generation antipsychotics was not associated with a significantly increased risk of major congenital malformations relative to no exposure.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: